Teva Pharmaceutical Industries announced positive results from the second Phase III HALO study of fremanezumab (TEV-48125), an investigational treatment for the prevention of migraine. In the episodic migraine (EM)
The Prescription Drug User Fee Act (PDUFA) date is January 24, 2018. TRULANCE is a once-daily tablet approved by the FDA for the treatment of adults with chronic
Stephen Hurly, President and Chief Executive Officer of Eleven Biotherapeutics said: "Despite current therapies and surgical regimens, there remains a large unmet need for patients with recurring or
The project will use AbCellera’s single-cell screening platform to profile vaccine-specific human antibodies elicited by seasonal influenza vaccination and to generate large panels of human monoclonal antibodies with
JCAR017 is Juno’s investigative chimeric antigen receptor (CAR) T cell product candidate that targets CD19, a protein expressed on the surface of almost all B cell malignancies, and
A search committee of the Board of Directors has been created and will begin conducting a thorough process to identify Mr. Hendrickson’s replacement. Mr. Hendrickson will remain with
Today’s decision makes Opdivo the first Immuno-Oncology agent approved in the European Union for the treatment of patients with this common type of bladder cancer. “Bladder cancer has
Under the terms of the agreement, Eloxx will become a wholly owned subsidiary of Sevion. Upon completion of the transaction, Sevion will change its name to Eloxx Pharmaceuticals,
Before Ebola virus ever struck West Africa, locals were already on the lookout for a deadly pathogen: Lassa virus. With thousands dying from Lassa every year—and the potential
The product will be renamed OBI-3424 effective immediately. OBI-3424 is a first-in-class prodrug that selectively releases a potent DNA alkylating agent in the presence of the AKR1C3 enzyme.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.